CHEMWERTH FORMS 2ND JOINT VENTURE IN CHINA

Partnering for Success – First FDA Approval
advantages have just gotten stronger!

Sichuan Credit Chemwerth Pharmaceutical Co. Ltd. (“CREDIT CHEMWERTH”), an API manufacturing company located in Luzhou City, Sichuan Province, China is the latest chemwerth Joint Venture. Established in October 2006, the JV is a partnership between chemwerth Inc., an API development and supply company respected as one of the industry’s foremost regulatory and technical service resources, and Sichuan Credit Pharmaceutical Co. Ltd., a Chinese manufacturer of API with strong R & D capabilities. 

Today’s challenges in the API manufacture and supply industry demand new perspectives and initiatives. CREDIT CHEMWERTH was established (in part) to keep pace with the growing competition and trend toward supply chain globalization. This strategic partnership significantly improves our ability to service our customers by further expanding our supply chain. With the diversity of core competencies of chemwerth and Credit, we can both benefit by combining and optimizing our individual strengths into one resource.

chemwerth has a proven 25-year history of success in the Chinese API industry. With an office in Shanghai since 1996, staffed with the highest-level chemists and regulatory professionals in China, we felt our established, physical presence was a key to bridging any gaps between culture, collaboration, and coordination in generating a successful business partnership. We chose Sichuan Credit Pharmaceuticals because they showed they have what it takes to be successful in the API business – dedication, commitment, expertise, and the desire to be the best.  

Sichuan Credit Pharmaceutical has reliable and strong API Research & Development and manufacturing capabilities. Staffed with 16 chemists, most with MS or BS degrees, working on the API process development, plus a multi-functional API workshop with full QC and QA support, equipped with HPLC, GC/Headspace, IR and other advanced analytical instruments, Credit already has 12 APIs that passed SFDA inspections. With the present support of chemwerth, their facility is in position to receive US FDA approval by early 2008. 

chemwerth expertise in market development, patent laws, regulatory affairs and technical services, combined with our own R & D capabilities and manufacturing cost advantages, positions CREDIT CHEMWERTH to accelerate new product development, registration and manufacturing time-lines. chemwerth can provide vital focus for better understanding of Customer demand, optimizing product launches, and managing and supporting QC/QA regulatory and compliance issues. All this translates to Customer Satisfaction, an element that is most important to chemwerth and Sichuan Credit.
 
As we see it, the CREDIT CHEMWERTH Joint Venture will enhance chemwerth’s position to be the leading USA supplier of reliable, high-quality Active Pharmaceutical Ingredients. At the same time, Chemwerth will provide Sichuan Credit the necessary technologies and support to secure and maintain FDA approved, cGMP compliant, and price competitive API to generic pharmaceutical Customers. Adding Weijie-Chemwerth (our R & D JV) and Credit to the total chemwerth package, makes us a strong and favorable choice for project selection, development, and sourcing. 

Together we can greatly help Customers accelerate the progress of API sourcing, supplier changes, new API development, key intermediate sourcing and finished dosage approval. First FDA Approval advantages for both API supplier and Finish Dosage Customers have just gotten stronger! Yet another reason to choose chemwerth – Your Guide to Pharmaceutical Success!